ImmunoGenesis doses 1st patient in phase 1/2 trial of IMGS-101 in combo with balstilimab & zalifrelimab to treat immune-excluded tumours: Houston Saturday, March 8, 2025, 18:00 Hr ...

BEIJING, March 13 (Xinhua) -- The Chinese capital plans to administer free human papillomavirus (HPV) vaccines to seventh-grade girls starting in September this year, joining several provincial-level ...

New trends data show significant reduction in the incidence of precancerous lesions in young women since advent of vaccine.

Researchers from the University of Chicago Medicine Comprehensive Cancer Center demonstrated the potential of a novel treatment approach including immunotherapy to treat advanced human papillomavirus ...

Vaxart (NASDAQ:VXRT – Get Free Report) is expected to release its earnings data before the market opens on Thursday, March ...

Sexually transmitted diseases (STDs), also known as sexually transmitted infections (STIs) or venereal diseases, are infections spread primarily through ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

The FDA has accepted for Priority Review the BLA for PRGN-2012 for the treatment of adults with recurrent respiratory papillomatosis.

ImmunoGenesis has initiated the first subject dosing in a multicentre Phase I/II trial of IMGS-101 (evofosfamide), the ...

Marking 30 years since the 1995 Beijing Declaration, the report notes global gains—girls’ life expectancy at 15 has risen to ...